ES2173172T3 - Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina. - Google Patents
Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina.Info
- Publication number
- ES2173172T3 ES2173172T3 ES95905164T ES95905164T ES2173172T3 ES 2173172 T3 ES2173172 T3 ES 2173172T3 ES 95905164 T ES95905164 T ES 95905164T ES 95905164 T ES95905164 T ES 95905164T ES 2173172 T3 ES2173172 T3 ES 2173172T3
- Authority
- ES
- Spain
- Prior art keywords
- vasopresine
- octocine
- dihydroindol
- nitrogenated
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN LA QUE R{SUB,1} Y R{SUB,2} REPRESENTAN CADA UNO INDEENDIENTEMENTE UN HIDROGENO; UN HALOGENO; UN ALKILO C{SUB,17}; UN ALCOXI C{SUB,1-7}; UN TRIFLUORMETILO. R{SUB,3} REPRESENTA UN ALKILO C{SUB,1-7}, UN CICLOALKILO C{SUB,3-7} UN CICLOHEXILO, UN CICLOXIMETILO, UN FENILO, UN BENCILO, R{SUB,4} REPRESENTA UN ACIDO, UN GRUPO 2,2-DIMETILHIODRACINO; UN ALKILSULFONAMIDO C{SUB,1-7}; UN PENILSULFONAMIDO; UN DIMETILAMINOSULFONAMIDO, UN GRUPO NR{SUB,7}R{SUB,8}; UN GRUPO NR{SUB,9}R{SUB,10}; UN GRUPO NR{SUB,9}R{SUB,11}; UN RADICAL HETEROCICLICO R{SUB,12}; UN PIPERACIN-1-ILO, UN GRUPO LACTOILAMINO, UN GRUPO MANDELOILAMINO; UN GRUPO N''-{(1-FENILETILUREIDO; UN GRUPO N''-{(1-NAFT-1ETIL)UREIDO; R{SUB,5} REPRESENTA HIDROGENO O UNO DE LOS VALORES REPRESENTANDOS PARA R{SUB,6}; R{SUB,6} REPRESENTA UN HALOGENO; UN ALKILO C{SUB,1-7}; UN TRIFULORMETILO; UN CIANO, UN AMINOMETILO, UN NITRO; UN GRUPO NR{SUB,9}R{SUB,11}; UN RADICAL HETEROCICLICO ELEGIDO ENTRE EL PIRROL-1-ILO EL {DE}3-PIRROLIN-1ILO, LA PIRROLIDIN-1-ILA, LA MORFOLIN-4-ILA; UN GRUPO OR{SUB,13}; UN GRUPO SR{SUB,13}, UN GUANIDINO, UN FORMILO; UN ALKILCARBONILO C{SUB,1-7}, UN CARBAMOILO, UN TIOCARBAMOILO, UN SULFAMOILO, UN CARBOXI; UN ALCOXICARBONILO C{SUB,1-7}; UN FENOXICARBONILO; UN BENCILOXICARBONILO; UN ALKILSULFONAMIDO C{SUB,1-7}M UNFENILSULFONAMIDO, UN DIMETILAMINOSULFONAMIDO; UN 2-{(METILFENILBENZAMIDO; O R{DUB,5} Y R{SUB,6} JUNTO CON ELFENILO AL QUE ESTA UNIDOS CONSTITUYEN UN GRUPO (A) SIEMPRE QUE X SEA -SO{SUB,2}; X REPRESENTA SO{SUB,2}; CH{SUB,2}. ESTOS COMPUESTOS TIENEN UNA AFINIDAD PARA LOS RECEPTORES DE LA VASOPRESINA Y/O LA OCITOCINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9315638A FR2714378B1 (fr) | 1993-12-24 | 1993-12-24 | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2173172T3 true ES2173172T3 (es) | 2002-10-16 |
Family
ID=9454390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95905164T Expired - Lifetime ES2173172T3 (es) | 1993-12-24 | 1994-12-23 | Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina. |
Country Status (10)
Country | Link |
---|---|
US (2) | US5594023A (es) |
EP (1) | EP0687251B1 (es) |
JP (1) | JP3263081B2 (es) |
AT (1) | ATE213727T1 (es) |
DE (1) | DE69429984T2 (es) |
DK (1) | DK0687251T3 (es) |
ES (1) | ES2173172T3 (es) |
FR (1) | FR2714378B1 (es) |
PT (1) | PT687251E (es) |
WO (1) | WO1995018105A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
TW359669B (en) * | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
AU4168999A (en) * | 1998-06-19 | 2000-01-05 | Wakamoto Pharmaceutical Co., Ltd. | Ocular tension lowering agents and phosphoric ester derivatives |
FR2792834A1 (fr) * | 1999-04-29 | 2000-11-03 | Sanofi Sa | Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud |
FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2804115B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2805536B1 (fr) | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
US6673790B1 (en) | 2000-04-03 | 2004-01-06 | Sanofi-Synthelabo | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
JP2003531853A (ja) * | 2000-05-03 | 2003-10-28 | スカンポ・アクチェンゲゼルシャフト | 眼圧降下剤 |
FR2810320B1 (fr) * | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
AU2003229735A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
CN100441965C (zh) * | 2003-08-26 | 2008-12-10 | 乐金电子(天津)电器有限公司 | 除湿器排放口的开关装置 |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
DE102004033834A1 (de) | 2004-07-13 | 2006-02-02 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel |
FR2875499B1 (fr) * | 2004-09-20 | 2006-10-27 | Sanofi Aventis Sa | Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique |
FR2880023B1 (fr) | 2004-12-23 | 2007-02-23 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique |
JP5125501B2 (ja) * | 2005-01-28 | 2013-01-23 | 大正製薬株式会社 | 1,3−ジヒドロ−2h−インドール−2−オン化合物、及び芳香族複素環が縮合したピロリジン−2−オン化合物 |
US7803834B2 (en) | 2005-03-24 | 2010-09-28 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, drugs containing said derivatives and the use thereof |
DE102005014904A1 (de) * | 2005-03-26 | 2007-02-01 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
DE102005014936A1 (de) * | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
CN101336239A (zh) * | 2005-12-02 | 2008-12-31 | 艾博特股份有限两合公司 | 经取代的羟吲哚衍生物,含有该衍生物的药物及其用途 |
JP5437070B2 (ja) * | 2006-08-26 | 2014-03-12 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換ベンゾイミダゾロン誘導体、それを含む薬剤およびそれの使用 |
DE102006040915A1 (de) * | 2006-08-26 | 2008-03-20 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2008107399A1 (en) | 2007-03-02 | 2008-09-12 | Abbott Gmbh & Co. Kg | Substituted oxindole compounds |
FR2920023B1 (fr) * | 2007-08-16 | 2013-02-08 | Sanofi Aventis | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique |
BRPI0820668A2 (pt) | 2007-12-07 | 2017-08-22 | Abbott Gmbh & Co Kg | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina |
WO2009071691A2 (de) * | 2007-12-07 | 2009-06-11 | Abbott Gmbh & Co. Kg | Oxindol-derivate und ihre verwendung als medikament |
JP5645217B2 (ja) | 2007-12-07 | 2014-12-24 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 5,6−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用 |
WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
JP5701607B2 (ja) * | 2007-12-07 | 2015-04-15 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
US8629148B2 (en) | 2007-12-27 | 2014-01-14 | AbbVie Deutschland GmbH & Co. KG | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
FR2927625B1 (fr) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
FR2930249B1 (fr) * | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
FR2941946B1 (fr) | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique |
FR2941947B1 (fr) | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique |
EP2435080A2 (en) | 2009-05-29 | 2012-04-04 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
ES2583061T3 (es) | 2010-12-21 | 2016-09-16 | Bayer Intellectual Property Gmbh | Método para la producción de oxindoles sustituidos en el N con sulfonilo |
FR2974576B1 (fr) | 2011-04-29 | 2013-07-19 | Sanofi Aventis | Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique |
CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3441570A (en) * | 1966-01-20 | 1969-04-29 | Parke Davis & Co | 3-tertiary aminoalkylamino-3-phenyl oxindole compounds |
GB1494340A (en) * | 1974-12-03 | 1977-12-07 | Wyeth John & Brother Ltd | Process for preparation of substituted n-phenylcarbamate esters |
DE2553662A1 (de) * | 1975-11-28 | 1977-06-08 | Edgar Griebel | Pressvorrichtung fuer muelltonnen |
FR2665441B1 (fr) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant. |
FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
-
1993
- 1993-12-24 FR FR9315638A patent/FR2714378B1/fr not_active Expired - Fee Related
-
1994
- 1994-12-23 DK DK95905164T patent/DK0687251T3/da active
- 1994-12-23 JP JP51781295A patent/JP3263081B2/ja not_active Expired - Fee Related
- 1994-12-23 WO PCT/FR1994/001528 patent/WO1995018105A1/fr active IP Right Grant
- 1994-12-23 PT PT95905164T patent/PT687251E/pt unknown
- 1994-12-23 ES ES95905164T patent/ES2173172T3/es not_active Expired - Lifetime
- 1994-12-23 EP EP95905164A patent/EP0687251B1/fr not_active Expired - Lifetime
- 1994-12-23 US US08/500,924 patent/US5594023A/en not_active Expired - Lifetime
- 1994-12-23 AT AT95905164T patent/ATE213727T1/de not_active IP Right Cessation
- 1994-12-23 DE DE69429984T patent/DE69429984T2/de not_active Expired - Fee Related
-
1996
- 1996-04-30 US US08/640,080 patent/US5773612A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2714378B1 (fr) | 1996-03-15 |
EP0687251A1 (fr) | 1995-12-20 |
DK0687251T3 (da) | 2002-06-03 |
DE69429984T2 (de) | 2002-10-17 |
DE69429984D1 (de) | 2002-04-04 |
US5594023A (en) | 1997-01-14 |
JPH08507092A (ja) | 1996-07-30 |
US5773612A (en) | 1998-06-30 |
EP0687251B1 (fr) | 2002-02-27 |
WO1995018105A1 (fr) | 1995-07-06 |
FR2714378A1 (fr) | 1995-06-30 |
ATE213727T1 (de) | 2002-03-15 |
PT687251E (pt) | 2002-08-30 |
JP3263081B2 (ja) | 2002-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2173172T3 (es) | Derivados de 1,3-dihidroindol-2-ona sustituidos en 3 por un grupo nitrogenado como agonistas y/o antagonistas de la vasopresina y/o de la octocina. | |
BR9303993A (pt) | Composto, processo para preparar o mesmo e composição farmacêutica | |
ES2123149T3 (es) | Derivados de perhidroisoindol como antagonistas de la substancia p. | |
ES2196072T3 (es) | Empleo de compuestos heterociclicos como ligandos de dopamina-d3. | |
DK0641328T3 (da) | Broforbundne, azabicykliske derivater som substans P-antagonister | |
ATE219764T1 (de) | Zimtsäurederivate und deren verwendung als integrin-antagonisten | |
ATE329901T1 (de) | 3-substituierte oxindolderivate als beta-3- agonisten | |
EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
NO970162L (no) | Substituerte pyrimidinforbindelser og anvendelse derav | |
AU4926301A (en) | Lpa receptor agonists and antagonists and methods of use | |
ES2132415T3 (es) | Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol. | |
ATE179703T1 (de) | Triazolverbindungen und deren verwendung als dopamin-d3-liganden | |
ES2092646T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
DE69214587T2 (de) | Methanoanthracene als Dopaminantagonisten | |
MX9604368A (es) | Antagonistas de receptores de endotelina. | |
AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
MX9301112A (es) | Derivados de indol. | |
PT854724E (pt) | Metodo de tratar a doenca navicular em cavalos | |
EA200301087A1 (ru) | Новые пиперидинкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции | |
MX9603199A (es) | Antagonistas de receptores a endotelina. | |
ES2143224T3 (es) | Derivados naftamida de 3-beta-amino azabiciclo octano o nonano, como agentes antipsicoticos. | |
EA200100918A1 (ru) | Агонисты 5-ht1f рецептора | |
BR0308890A (pt) | Composto | |
NO994135D0 (no) | Kinoksalindioner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 687251 Country of ref document: ES |